

# Gianni Sava

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4855782/publications.pdf>

Version: 2024-02-01

125  
papers

8,578  
citations

71004

43  
h-index

51423

90  
g-index

126  
all docs

126  
docs citations

126  
times ranked

7818  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of NAMI-A Cytotoxic Effects toward Leukemia Cell Lines: A Slippery Ground Giving Misleading Messages. <i>Critical Reviews in Oncogenesis</i> , 2021, 26, 73-78.	0.2	2
2	Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. <i>Journal of Autoimmunity</i> , 2021, 122, 102685.	3.0	53
3	Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice. <i>International Journal of Food Sciences and Nutrition</i> , 2021, 72, 37-44.	1.3	12
4	Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. <i>Journal of Autoimmunity</i> , 2021, 125, 102742.	3.0	42
5	Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3923.	1.8	22
6	Lysozyme-Induced Transcriptional Regulation of TNF- $\alpha$ Pathway Genes in Cells of the Monocyte Lineage. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5502.	1.8	21
7	A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53. <i>Cancer Letters</i> , 2019, 440-441, 145-155.	3.2	28
8	The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. <i>Coordination Chemistry Reviews</i> , 2018, 360, 17-33.	9.5	94
9	Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1663-1670.	0.8	3
10	Chemical and Molecular Approach to Tumor Metastases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 843.	1.8	3
11	Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A. <i>Journal of Inorganic Biochemistry</i> , 2017, 168, 90-97.	1.5	10
12	The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1869.	1.8	25
13	Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1254.	1.8	11
14	Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in <i>Procambarus clarkii</i> . <i>Aquaculture</i> , 2016, 463, 209-216.	1.7	8
15	Inhibition of adhesion, migration and of $\alpha_5\beta_1$ integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 225-235.	1.5	30
16	Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through $\alpha_5\beta_1$ Integrin. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 2385-2396.	1.2	28
17	Effects of Two Fullerene Derivatives on Monocytes and Macrophages. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	16
18	Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from <i>Mytilus galloprovincialis</i> . <i>Genome Biology and Evolution</i> , 2015, 7, 2203-2219.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Linking the future of anticancer metal-complexes to the therapy of tumour metastases. <i>Chemical Society Reviews</i> , 2015, 44, 8818-8835.	18.7	190
20	RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A. <i>Metallomics</i> , 2015, 7, 1439-1450.	1.0	15
21	Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. <i>Investigational New Drugs</i> , 2015, 33, 201-214.	1.2	327
22	Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer. <i>Investigational New Drugs</i> , 2015, 33, 53-63.	1.2	32
23	Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an <i>in-vitro</i> model of human proximal tubular epithelial cells. <i>Experimental Biology and Medicine</i> , 2014, 239, 337-346.	1.1	16
24	A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival. <i>Nano-Micro Letters</i> , 2014, 6, 163-168.	14.4	14
25	Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo. <i>Journal of Membrane Biology</i> , 2014, 247, 1239-1251.	1.0	12
26	Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq. <i>Toxicology</i> , 2013, 314, 183-192.	2.0	31
27	Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice. <i>Journal of Inorganic Biochemistry</i> , 2013, 118, 21-27.	1.5	15
28	Microencapsulation of Bioactive Principles with an Airless Spray-Gun Suitable for Processing High Viscous Solutions. <i>Journal of Functional Biomaterials</i> , 2013, 4, 312-328.	1.8	2
29	CDK1 Hyperphosphorylation Maintenance Drives the Time-course of G2-M Cell Cycle Arrest after Short Treatment with NAMI-A in Kb Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 949-958.	0.9	10
30	Synthesis and characterization of a diruthenium(II,III) ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives. <i>Polyhedron</i> , 2012, 42, 175-181.	1.0	30
31	Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. <i>Biochemical Pharmacology</i> , 2012, 84, 1428-1436.	2.0	58
32	Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs. <i>Dalton Transactions</i> , 2012, 41, 8226.	1.6	94
33	Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells. <i>Journal of Nanoparticle Research</i> , 2012, 14, 1.	0.8	38
34	Metal-Based Inhibition of Poly(ADP-ribose) Polymerase ~ The Guardian Angel of DNA. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2196-2206.	2.9	137
35	Metal-based antitumour drugs in the post-genomic era: what comes next?. <i>Dalton Transactions</i> , 2011, 40, 9069.	1.6	220
36	Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. <i>Dalton Transactions</i> , 2011, 40, 7817.	1.6	384

#	ARTICLE	IF	CITATIONS
37	Organometallic ruthenium-based antitumor compounds with novel modes of action. <i>Journal of Organometallic Chemistry</i> , 2011, 696, 989-998.	0.8	324
38	Ruthenium <sup>II</sup> Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4678-4690.	2.9	120
39	Ruthenium Drugs for Cancer Chemotherapy: An Ongoing Challenge to Treat Solid Tumours. , 2009, , 57-66.		8
40	Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 511-520.	1.1	37
41	Influence of the anionic ligands on the anticancer activity of Ru(II) <sup>II</sup> dmsocomplexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 606-617.	1.5	19
42	Half-sandwich Ru(II) complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 1120-1133.	1.5	43
43	Oral poly(ethylene glycol)-conjugated human recombinant lysozyme control of lung metastases in mice. <i>Molecular Medicine Reports</i> , 2008, 1, 847-50.	1.1	2
44	Inhibition of Human Pancreatic Cell Line MIA PaCa2 Proliferation by HA-But, a Hyaluronic Butyric Ester. <i>Pancreas</i> , 2008, 36, e15-e23.	0.5	19
45	Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. <i>International Journal of Oncology</i> , 2008, 33, 1281-9.	1.4	34
46	Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2166-2175.	2.9	173
47	Tuning the hydrophobicity of ruthenium(II) <sup>II</sup> arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. <i>Dalton Transactions</i> , 2007, , 5065.	1.6	131
48	Metal Based Drugs Restyled and Resumed. <i>Metal-Based Drugs</i> , 2007, 2007, 1-1.	3.8	0
49	Novel platinum pyridinehydroxamic acid complexes: Synthesis, characterisation, X-ray crystallographic study and nitric oxide related properties. <i>Polyhedron</i> , 2007, 26, 4697-4706.	1.0	21
50	Synthesis, Characterization, and in Vitro Evaluation of Novel Ruthenium(II) <sup>II</sup> -6-Arene Imidazole Complexes. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5552-5561.	2.9	137
51	Metal-based antitumour drugs in the post genomic era. <i>Dalton Transactions</i> , 2006, , 1929.	1.6	698
52	Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds. <i>Organometallics</i> , 2006, 25, 756-765.	1.1	154
53	The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. <i>International Journal of Oncology</i> , 2006, 29, 261-8.	1.4	12
54	Platinum(II) Complexes with Antitumoral/Antiviral Aromatic Heterocycles: Effect of Glutathione upon in Vitro Cell Growth Inhibition. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3364-3371.	2.9	37

#	ARTICLE	IF	CITATIONS
55	In Vitro and in Vivo Evaluation of Ruthenium(II) Arene PTA Complexes. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4161-4171.	2.9	723
56	Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But. <i>Clinical Cancer Research</i> , 2004, 10, 4822-4830.	3.2	82
57	Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its hemolytic potential. <i>Journal of Oncology Pharmacy Practice</i> , 2004, 10, 7-15.	0.5	1
58	Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. <i>International Journal of Oncology</i> , 2004, 24, 373.	1.4	1
59	Ruthenium Antimetastatic Agents. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1525-1535.	1.0	452
60	Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. <i>Investigational New Drugs</i> , 2004, 22, 207-217.	1.2	37
61	Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L=o-tolylazopyridine) Tj ETQq1 1 0.784314 rgBT /Over Chemistry, 2004, 9, 354-364.	1.1	80
62	Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1385-1390.	1.5	30
63	Cocultures of metastatic and host immune cells; selective effects of NAMI-A for tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 1101-1110.	2.0	20
64	Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 301-312.	1.5	117
65	Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 393-401.	1.5	47
66	The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 402-412.	1.5	163
67	Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl4(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 984-990.	1.5	66
68	TGF $\beta$ 1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1648-1654.	1.5	23
69	Intratumoral NAMI-A Treatment Triggers Metastasis Reduction, Which Correlates to CD44 Regulation and Tumor Infiltrating Lymphocyte Recruitment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 737-744.	1.3	67
70	Synthesis and Chemical~Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp) [trans-RuCl4(dmsO-S)(dmtP)], (Na) [trans-RuCl4(dmsO-S)(dmtP)], and [mer-RuCl3(H2O)(dmsO-S)(dmtP)] (dmtP = 5,7-Dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1110-1121.	2.9	118
71	Ruthenium Anticancer Drugs. , 2004, , 323-351.		84
72	Ruthenium anticancer drugs. <i>Metal Ions in Biological Systems</i> , 2004, 42, 323-51.	0.4	14

#	ARTICLE	IF	CITATIONS
73	Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration. <i>Investigational New Drugs</i> , 2003, 21, 55-62.	1.2	36
74	Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl <sub>4</sub> (Im)(DMSO)], (I) and of the orange form of [(DMSO) <sub>2</sub> H][trans-IrCl <sub>4</sub> (DMSO) <sub>2</sub> ], (II), complexes. <i>Journal of Inorganic Biochemistry</i> , 2003, 95, 37-46.	1.5	52
75	Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 31, 215-228.	1.4	28
76	Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 725-732.	1.3	25
77	Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. <i>Clinical Cancer Research</i> , 2003, 9, 1898-905.	3.2	184
78	Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 339-348.	1.3	71
79	The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. <i>Archives of Biochemistry and Biophysics</i> , 2002, 403, 209-218.	1.4	63
80	A review on usnic acid, an interesting natural compound. <i>Die Naturwissenschaften</i> , 2002, 89, 137-146.	0.6	303
81	Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 405-411.	1.1	31
82	Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. <i>FEBS Journal</i> , 2002, 269, 5861-5870.	0.2	67
83	Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 30, 1287-1296.	1.4	18
84	A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. <i>International Journal of Pharmaceutics</i> , 2002, 248, 239-246.	2.6	67
85	Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. <i>International Journal of Oncology</i> , 2002, 21, 1331-8.	1.4	19
86	Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma. <i>Metal-Based Drugs</i> , 2001, 8, 1-7.	3.8	39
87	Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na <sub>2</sub> [{trans-RuCl <sub>4</sub> (Me <sub>2</sub> SO)} <sub>2</sub> (L-L)] (L=ditopic, non-chelating aromatic N-ligand). A preliminary investigation. <i>Journal of Inorganic Biochemistry</i> , 2000, 79, 173-177.	1.5	20
88	Blood Concentration and Toxicity of the Antimetastasis Agent NAMI-A Following Repeated Intravenous Treatment in Mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000, 87, 193-197.	0.0	69
89	Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth. <i>Pathology and Oncology Research</i> , 1999, 5, 110-116.	0.9	3
90	Sulfoxide Ruthenium Complexes: Non-Toxic Tools for the Selective Treatment of Solid Tumour Metastases. , 1999, , 143-169.		34

#	ARTICLE	IF	CITATIONS
91	Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: The crystal structure of [ImH][trans-RhCl <sub>4</sub> (Im) <sub>2</sub> ] (Im=imidazole). <i>Inorganica Chimica Acta</i> , 1998, 273, 62-71.	1.2	62
92	Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry. <i>Chemico-Biological Interactions</i> , 1998, 113, 51-64.	1.7	12
93	Comparison of the effects of the antimetastatic compound ImH[trans-RuCl <sub>4</sub> (DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice. <i>Pathology and Oncology Research</i> , 1998, 4, 30-36.	0.9	36
94	Treatment of residual metastases with Na[trans-RuCl <sub>4</sub> (DMSO)Im] and ruthenium uptake by tumor cells. <i>Anti-Cancer Drugs</i> , 1996, 7, 697-702.	0.7	31
95	Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex. , 1996, 68, 60-66.		68
96	Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. <i>Chemico-Biological Interactions</i> , 1995, 95, 109-126.	1.7	80
97	Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl <sub>4</sub> (DMSO)Im] in the mouse. <i>Clinical and Experimental Metastasis</i> , 1994, 12, 93-100.	1.7	59
98	Ruthenium compounds in cancer therapy. , 1994, , 65-91.		6
99	Response of MCa Mammary Carcinoma to Cisplatin and to Na[trans-RuCl <sub>4</sub> (DMSO)Im]. <i>Drug Investigation</i> , 1994, 8, 150-161.	0.6	34
100	Anti-leukaemic action of RuCl <sub>2</sub> (DMSO) <sub>4</sub> isomers and prevention of brain involvement on P388 leukaemia and on subline. <i>European Journal of Cancer</i> , 1993, 29, 1873-1879.	1.3	66
101	Effects of the Ru(III) complexes [mer-RuCl <sub>3</sub> (DMSO) <sub>2</sub> Im] <sup>+</sup> and Na[trans-RuCl <sub>4</sub> (DMSO)Im] on solid mouse tumors. <i>Anti-Cancer Drugs</i> , 1992, 3, 25-32.	0.7	56
102	Na[trans-RuCl <sub>4</sub> (DMSO)Im], a metal complex of ruthenium with antimetastatic properties. <i>Clinical and Experimental Metastasis</i> , 1992, 10, 273-80.	1.7	83
103	Antineoplastic effects of mer-trichlorobisdimethylsulphoxideaminoruthenium(III) against murine tumors: Comparison with cisplatin and with ImH[RuCl <sub>2</sub> Cl <sub>2</sub> ]. <i>Chemico-Biological Interactions</i> , 1991, 78, 223-234.	1.7	22
104	Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 27, 423-428.	1.1	0
105	Metal complexes of ruthenium. <i>Anti-Cancer Drugs</i> , 1990, 1, 99-108.	0.7	34
106	Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 25, 221-222.	1.1	25
107	Effects of two pyridinalalkyliminorhodium(I) complexes in mice bearing MCa mammary carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, 302-306.	1.1	11
108	Antitumour properties of dimethylsulphoxide ruthenium(II) complexes in the Lewis lung carcinoma system. <i>Pharmacological Research</i> , 1989, 21, 617-628.	3.1	62

#	ARTICLE	IF	CITATIONS
109	Antimetastatic action of orally administered lysozyme in mice bearing Lewis lung carcinoma. <i>Clinical and Experimental Metastasis</i> , 1988, 6, 245-253.	1.7	13
110	Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 21, 241-5.	1.1	8
111	Evidence for host-mediated antitumor effects of lysozyme in mice bearing the MCa mammary carcinoma. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 1737-1743.	0.9	31
112	Cis- and trans-dihalotetrakis(dimethyl sulfoxide)ruthenium(II) complexes (RuX <sub>2</sub> (DMSO) <sub>4</sub> ; X = Cl, Br): synthesis, structure, and antitumor activity. <i>Inorganic Chemistry</i> , 1988, 27, 4099-4106.	1.9	323
113	Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. <i>Clinical and Experimental Metastasis</i> , 1987, 5, 27-34.	1.7	6
114	Tumor animal models used for evaluating the antineoplastic activity of platinum coordination complexes. <i>Inorganica Chimica Acta</i> , 1987, 137, 39-44.	1.2	0
115	Coordination metal complexes of Rh(I), Ir(I) and Ru(II): recent advances on antimetastatic activity on solid mouse tumors. <i>Inorganica Chimica Acta</i> , 1987, 137, 69-71.	1.2	34
116	Mutagenic activity of the dacarbazine analog p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt in bacterial cells. <i>Pharmacological Research Communications</i> , 1986, 18, 491-501.	0.2	6
117	Infiltration of Liver and Brain by Tumor Cells in Leukemic Mice: Prevention by Dimethyltriazenes and Cyclophosphamide. <i>Tumori</i> , 1984, 70, 477-483.	0.6	5
118	Selective Antimetastatic Triazenes: A Quantitative Approach. <i>QSAR and Combinatorial Science</i> , 1984, 3, 59-62.	1.4	12
119	Antitumor and antimetastatic activity of the immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa mammary carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 1984, 18, 49-53.	2.0	14
120	Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1984, 20, 961-966.	0.9	4
121	Effects of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1984, 20, 287-289.	0.9	3
122	Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma. <i>Chemico-Biological Interactions</i> , 1983, 45, 1-6.	1.7	68
123	Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 1983, 10, 167-9.	1.1	2
124	Synthesis of l-Aryl-3-formyl-3-methyltriazenes, Potential Metabolites of l-Aryl-3,3-dimethyltriazenes. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 1098-1099.	1.6	6
125	Investigation on the oxidative N-demethylation of aryl triazenes In vitro. <i>Biochemical Pharmacology</i> , 1975, 24, 1793-1797.	2.0	23